What Dalvance Treats: Main Uses and Benefits

Targeting Acute Skin and Soft Tissue Infections

Dalvance is commonly used across conditions presenting with acute episodes of severe bacterial infections in the skin and underlying soft tissues. It is considered relevant in contexts involving heightened systemic burden, specifically for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This includes conditions like severe cellulitis, major abscesses, and complex wound infections. It is applied in addressing situations where Gram-positive bacteria, including the challenging Methicillin-Resistant Staphylococcus aureus (MRSA), create noticeable physiological strain. Therapeutic application may assist with maintaining functional stability by easing pronounced local symptoms, such as widespread redness, deep swelling, intense pain, and fever.

Facilitating Simplified Intravenous Treatment

This medication is applied in clinical settings that involve acute symptom patterns and where short-term symptomatic assistance is needed outside of a traditional inpatient facility. The main therapeutic benefit is commonly used to help with management by offering powerful systemic support. This simplified approach supports general well-being and may assist with maintaining functional stability, which is considered relevant in contexts where earlier transition from the hospital or avoidance of a prolonged stay is appropriate. It contributes to improved comfort during symptomatic periods.

“This medication is primarily relevant for easing the symptom burden caused by infections that create significant physiological strain.”

The main therapeutic benefit is commonly used to help with management by offering powerful systemic support, which contributes to improved comfort during symptomatic periods.

---

Quick Fact: Symptom Domains Related to Acute Infection

Symptom Domain	Relief Focus
Local Strain	Focus on pronounced redness (erythema) and deep swelling (edema)
Pain/Discomfort	Relevant for managing intense localized pain
Systemic Burden	Relevant for managing infection-related fever

Who Can and Cannot Use Dalvance?

Eligibility for Dalvance ( dalbavancin) is defined by regulatory agencies based on the patient's health status, age, and potential allergic history.

Contraindications and Restrictions

Category	Status (Official Regulatory Statement)
Absolute Contraindication	Patients with a known hypersensitivity to dalbavancin must not use the medicine.
Age-Group Eligibility	Approved for adults and pediatric patients from birth onward. No general dose adjustment is required for older adults.
Renal Impairment	Adults with severe renal impairment ( CLcr < 30 mL/ min) not receiving regular hemodialysis require a specified dosage reduction. Use in pediatric patients with this level of impairment has insufficient data for a dose recommendation.
Hepatic Impairment	Caution should be exercised in patients with moderate or severe hepatic impairment (Child-Pugh B or C), as no data are available to determine appropriate dosing.
Pregnancy/Lactation	Pregnancy: Use is conditional on a risk-benefit assessment; European regulators state use is not recommended unless the potential benefit clearly justifies the risk. Lactation: Conditional use based on weighing the mother's need against potential infant exposure.

The medicine is restricted to treating infections that are proven or strongly suspected to be caused by susceptible Gram-positive bacteria.

Dalvance’s official interaction profile details potential pharmacokinetic changes and mandatory administration restrictions. The drug has a low potential for metabolic drug interactions because it is not significantly metabolized by the Cytochrome P450 (CYP) enzyme system and is not an inhibitor or inducer of these enzymes. This low-risk classification applies to many other medicines that rely on CYP pathways for their clearance.

However, formal caution is documented regarding drug transporters. Co-administration with inhibitors of hepatic uptake and efflux transporters may result in an increased systemic exposure of Dalbavancin. Conversely, increased exposure of certain sensitive transporter substrates, such as statins and digoxin, cannot be excluded when combined with Dalvance.

Mandatory restrictions govern the preparation and administration procedure. Dalvance must not be co-infused with other medications or electrolytes in the same intravenous line. Saline-based infusion solutions are restricted from use due to the risk of precipitation. If a common IV line is used for sequential drug administration, the line must be flushed with 5% Dextrose Injection, USP both before and after the Dalvance infusion. Furthermore, official labeling confirms that no known interactions with food or alcohol are documented.

Targeted Inhibition of Bacterial Cell Wall Assembly

Dalbavancin is an inhibitor designed to act at the final, crucial steps of bacterial cell wall biosynthesis. Its mechanism involves high-affinity binding to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors, which physically blocks the cross-linking enzymes necessary to build the cell's rigid, protective mesh. This action leads to the structural integrity of the bacteria being structurally impaired.

Dual Mechanism: Anchoring and Enhanced Potency

The mechanism is enhanced by a lipophilic side chain that anchors the drug molecule into the bacterial cell membrane, stabilizing the interaction at the target site. This anchoring facilitates drug dimerization, which increases the drug's affinity and local concentration. The resulting physiological effect is the rapid loss of osmotic stability, causing the bacterial cell to rupture, a process known as the bactericidal effect.

Mechanistic Constraints and Target Modification Evasion

The function of this mechanism is constrained by the specific molecular structure of the target. The drug cannot effectively bind to the altered D-Ala-D-Lactate structure found in resistant organisms like those carrying VanA/VanB genes. Furthermore, the mechanism is entirely ineffective against Gram-negative bacteria due to their protective outer membrane, which prevents the drug from reaching its cell wall target.

Administration Protocol

Dalvance (dalbavancin) is administered exclusively via Intravenous (IV) infusion. The medication is supplied as a lyophilized powder that requires specific preparation before use: it must first be reconstituted and then diluted only with 5% Dextrose Injection, USP (D5W) to a final concentration between 1 mg/mL and 5 mg/mL. Saline-based solutions must not be used for dilution or flushing the IV line. Each prescribed dose must be infused over a period of 30 minutes.

Official Dosing Schedules

The official dosing protocols define a full course of treatment using one of two schedules:

• Single-Dose Regimen: 1,500 mg administered once.
• Two-Dose Regimen: 1,000 mg on Day 1, followed by 500 mg one week later (Day 8).

If the second dose of the two-dose regimen is missed, it should be administered as soon as possible, with the next dose following one week after the late dose.

Population-Specific Use Rules

Dose adjustments are required for adult patients with significant renal impairment (creatinine clearance < 30 mL/min and not on regular hemodialysis), necessitating a reduced total dose (1,125 mg single dose or 750 mg / 375 mg two-dose). No dosage adjustment is required for adults on regular hemodialysis. Pediatric patients (ge 3 months to < 18 years) receive a weight-based single dose, with a maximum dose of 1,500 mg.

---

The instructions define a highly standardized process requiring sterile preparation and a mandatory 30-minute IV infusion time per dose, ensuring the complete course of therapy is delivered in a low-frequency schedule.

Dalvance: Recent Clinical Evidence

Dalbavancin is a semisynthetic lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Key Clinical Study Findings

Initial approval was based on two Phase 3 randomized, double-blind trials (Trial 1 and Trial 2) that compared dalbavancin with vancomycin (with an option to switch to oral linezolid). The primary endpoint in both trials was the early clinical response, defined as the absence of an increase in the lesion size 48 to 72 hours after the start of therapy, without the use of rescue antibiotics. Results suggested that dalbavancin was noninferior to the comparator regimen in achieving this early clinical response.

Primary Trial Endpoint	Dalbavancin Regimen	Comparator Regimen
Early Clinical Response	Noninferiority shown	Standard therapy (vancomycin)

Extended Treatment Research

Recent research has explored the use of dalbavancin for more invasive and difficult-to-treat infections, such as complicated Staphylococcus aureus bacteremia (SAB) and osteomyelitis (bone infection), which typically require prolonged intravenous therapy.

A Phase 2b trial for complicated SAB investigated dalbavancin compared to standard long-course IV treatment. The study found that dalbavancin met the noninferiority margin for overall clinical success, suggesting similar effectiveness to standard therapy. The long half-life of dalbavancin allows for a single-dose or two-dose regimen, which may offer an alternative to prolonged IV access for certain patients.

Safety findings across clinical trials consistently report that adverse events are generally comparable between dalbavancin and the active comparator treatments.

Common questions about Dalvance (FAQ)

Q: What is Dalvance (dalbavancin) and how does it work?

A: Dalvance is an intravenous (IV) antibiotic used to treat certain serious skin infections, such as acute bacterial skin and skin structure infections (ABSSSI). It belongs to a class of antibiotics called lipoglycopeptides.

Dalvance works by targeting and killing susceptible Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), which are often the cause of these skin infections. It interferes with the bacteria's ability to build and repair their cell walls, leading to the death of the bacterial cell.

---

Q: How is Dalvance typically given?

A: Dalvance is administered by a healthcare professional through an intravenous (IV) infusion into a vein. It is typically given as a short-course treatment over one or two doses, depending on the prescribing information and the severity of the infection.

• Single-Dose Regimen: A single, high dose (e.g., 1500 mg) may be infused over 30 minutes.
• Two-Dose Regimen: An initial dose (e.g., 1000 mg) is followed by a second, lower dose (e.g., 500 mg) one week later. Both doses are infused over 30 minutes.

The specific regimen and dose are determined by your doctor based on your infection and overall health.

---

Q: What are the potential side effects of Dalvance?

A: Like all medicines, Dalvance can cause side effects, though not everyone experiences them. Common side effects may include:

• Nausea or vomiting
• Diarrhea
• Headache
• Changes in certain liver enzyme tests (seen in blood tests)
• Infusion-related reactions (see below)

Rare but serious side effects can include a severe allergic reaction (anaphylaxis) or a potentially serious skin reaction called DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). You should seek immediate medical attention if you experience signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, or difficulty breathing.

---

Q: What is an infusion-related reaction, and what should I watch for?

A: An infusion-related reaction is a common side effect that can occur during or shortly after the IV infusion of Dalvance. These reactions are typically mild to moderate and may be related to the rate at which the medication is infused.

Symptoms to watch for include:

• Flushing (redness of the skin)
• Hives or itching
• Rash
• Feeling dizzy or lightheaded

To help minimize the risk, Dalvance is administered slowly over at least 30 minutes. If a reaction occurs, the infusion may be slowed down or temporarily stopped. It is important to tell your healthcare provider immediately if you experience any of these symptoms during your infusion.

---

Q: Can Dalvance cause Clostridium difficile-associated diarrhea (CDAD)?

A: Yes. Nearly all antibiotics, including Dalvance, can alter the normal balance of bacteria in the colon, which may allow an overgrowth of Clostridium difficile bacteria. This can cause CDAD (also known as antibiotic-associated diarrhea), which can range in severity from mild diarrhea to severe, life-threatening inflammation of the colon (colitis).

If you develop watery or bloody diarrhea, fever, or abdominal cramps during or after treatment with Dalvance, contact your healthcare professional immediately.

Storage and Disposal of Dalvance

Storage requirements for Dalvance (dalbavancin) are defined by its form, strictly adhering to regulatory labeling.

Required Storage Conditions

Product Form	Temperature Range	Stability Constraint
Unreconstituted Powder	25 C (77 F)	Store at controlled room temperature.
Prepared Solution	2 C to 8 C (Refrigerated) OR 20 C to 25 C (Room Temp)	Total time from reconstitution to administration must not exceed 48 hours.

Mandatory Handling and Disposal

The prepared solution must not be frozen. Containers for the dry powder should be kept tightly closed. To ensure product stability, the solution must be visually inspected for particulate matter prior to use. Any unused portion of the prepared solution must be discarded. Disposal of the contents and container must be carried out through an approved waste disposal plant in accordance with local and national regulations.